RefleXion Medical Launches Pivotal Study for SCINTIX Therapy
RefleXion Medical, a leader in innovative oncology solutions, has embarked on an exciting journey with the initiation of the BIOGUIDE-X2 clinical study. This significant advancement aims to expand the indications for their SCINTIX therapy, a transformative biology-guided radiotherapy designed to enhance treatment options for cancer patients.
Details of the BIOGUIDE-X2 Clinical Study
The BIOGUIDE-X2 study will focus initially on patients battling cancers in the liver and abdomen. The goal is to gather crucial data from various clinical sites to support the inclusion of SCINTIX therapy as a viable treatment for diverse solid tumor cancers. This study reflects RefleXion’s commitment to providing innovative solutions for cancer treatment.
Expanding Treatment Access
With the updated Centers for Medicare and Medicaid Services (CMS) reimbursement policies, RefleXion is set to increase access to SCINTIX therapy. Scheduled to take effect in 2025, these updates will introduce new reimbursement codes for freestanding cancer centers, allowing more patients to receive this promising treatment.
Benefits of Medicare Reimbursement Updates
Approximately 400,000 additional patients will have the chance to access SCINTIX therapy thanks to the updated reimbursement policies. This change acknowledges the increased effort from physicians, ensuring they receive professional payment coding to facilitate the widespread adoption of this groundbreaking technology.
Insights from RefleXion Leadership
Sean Shirvani, M.D., M.P.H., chief medical officer at RefleXion, expressed enthusiasm about these significant milestones. “These developments set the stage for substantial expansion in both the indications for and access to SCINTIX therapy. Securing reimbursement for freestanding centers is pivotal, as it eliminates payment barriers that providers face when adopting new technologies,” he commented.
About SCINTIX Therapy
SCINTIX therapy stands out in the field of oncology by using a single radiotracer injection to turn cancer cells into real-time biological beacons. This innovative approach allows for precise delivery of external-beam radiotherapy to targeted tumors. Currently, SCINTIX is indicated for the treatment of lung and bone tumors, but ongoing studies aim to broaden its scope significantly.
Future Research and Development
RefleXion's dedication to transforming cancer care is further demonstrated through the BIOGUIDE-X2 study's multi-cohort design, which aims to extend SCINTIX therapy's reach beyond lung and bone cancers to include various solid tumor types. This groundbreaking research will be conducted at six clinical sites, fostering collaboration among leading cancer treatment facilities.
About RefleXion Medical
Headquartered in Hayward, California, RefleXion Medical develops and commercializes cutting-edge therapies for cancer treatment. The company remains at the forefront of integrating advanced technology with oncology, aiming to make strides in treatment outcomes for patients facing cancer.
Frequently Asked Questions
What is the purpose of the BIOGUIDE-X2 clinical study?
The BIOGUIDE-X2 study seeks to expand the indications for SCINTIX therapy, focusing on cancers located in the liver and abdomen.
How will Medicare reimbursement changes affect patients?
The upcoming changes will broaden access to SCINTIX therapy for approximately 400,000 additional patients starting in 2025.
What are the benefits of SCINTIX therapy?
SCINTIX therapy enhances treatment precision by using a single radiotracer injection to guide radiotherapy delivery directly to tumors.
Who leads RefleXion Medical?
Sean Shirvani, M.D., M.P.H. serves as the chief medical officer, guiding the company’s clinical strategies and innovations.
What types of cancers can SCINTIX therapy treat?
Currently, SCINTIX therapy is indicated for lung and bone tumors, with ongoing research aimed at expanding its application to other solid tumors.
